Dyskinesia – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Dyskinesia – Pipeline Review, H2 2017’, provides an overview of the Dyskinesia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Dyskinesia

The report reviews pipeline therapeutics for Dyskinesia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Dyskinesia therapeutics and enlists all their major and minor projects

The report assesses Dyskinesia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Dyskinesia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Dyskinesia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Dyskinesia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adamas Pharmaceuticals Inc

Addex Therapeutics Ltd

Advicenne SA

Avanir Pharmaceuticals Inc

Bionomics Ltd

Catalyst Biosciences Inc

Cavion LLC

Clevexel Pharma SAS

EpiVax Inc

Heptares Therapeutics Ltd

Ipsen SA

Merz Pharma GmbH & Co KgaA

Neurim Pharmaceuticals Ltd

Neurocrine Biosciences Inc

Neurolixis Inc

Osmotica Pharmaceutical Corp

Phenomenome Discoveries Inc

Sage Therapeutics Inc

SciFluor Life Sciences LLC

SOM Biotech SL

Synchroneuron Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 7

Global Markets Direct Report Coverage 7

Dyskinesia - Overview 8

Dyskinesia - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 17

Dyskinesia - Therapeutics Assessment 18

Assessment by Target 18

Assessment by Mechanism of Action 21

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Dyskinesia - Companies Involved in Therapeutics Development 28

Adamas Pharmaceuticals Inc 28

Addex Therapeutics Ltd 28

Advicenne SA 29

Avanir Pharmaceuticals Inc 29

Bionomics Ltd 29

Catalyst Biosciences Inc 30

Cavion LLC 30

Clevexel Pharma SAS 31

EpiVax Inc 31

Heptares Therapeutics Ltd 31

Ipsen SA 32

Merz Pharma GmbH & Co KgaA 32

Neurim Pharmaceuticals Ltd 33

Neurocrine Biosciences Inc 33

Neurolixis Inc 33

Osmotica Pharmaceutical Corp 34

Phenomenome Discoveries Inc 34

Sage Therapeutics Inc 35

SciFluor Life Sciences LLC 35

SOM Biotech SL 35

Synchroneuron Inc 36

Dyskinesia - Drug Profiles 37

(dextromethorphan + quinidine sulfate) - Drug Profile 37

A-2M13677 - Drug Profile 42

abobotulinumtoxinA - Drug Profile 43

acamprosate calcium SR - Drug Profile 47

amantadine hydrochloride ER - Drug Profile 49

amantadine hydrochloride ER - Drug Profile 59

AT-127 - Drug Profile 60

AT-326 - Drug Profile 61

AT-403 - Drug Profile 62

befiradol - Drug Profile 63

brexanolone - Drug Profile 65

CVXL-0107 - Drug Profile 74

CX-8998 - Drug Profile 75

cycloserine - Drug Profile 76

dipraglurant IR - Drug Profile 77

Drug for Dyskinesia - Drug Profile 82

Drug for Tardive Dyskinesia - Drug Profile 83

Drugs for Dyskinesia - Drug Profile 84

Gene Therapy to Inhibit TRH for Dyskinesia - Drug Profile 85

HTL-14242 - Drug Profile 86

incobotulinumtoxin A - Drug Profile 87

IRL-790 - Drug Profile 92

JM-010 - Drug Profile 93

MLR-1019 - Drug Profile 95

NBI-640756 - Drug Profile 96

Neu-120 - Drug Profile 97

Neu-240 - Drug Profile 98

onabotulinumtoxinA - Drug Profile 99

PCT-3010 - Drug Profile 100

PPI-1011 - Drug Profile 101

RNAi Gene Therapy to Inhibit NURR1 for Dyskinesia - Drug Profile 102

SAGE-217 - Drug Profile 103

SK-609 - Drug Profile 107

Small Molecule for Dyskinesia - Drug Profile 108

Small Molecule for Dyskinesia - Drug Profile 109

Small Molecules for Neurodegenerative Disease - Drug Profile 110

Small Molecules to Antagonize GPCR for Central Nervous System Diseases - Drug Profile 111

Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia - Drug Profile 112

Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile 113

Small Molecules to Antagonize mGluR5 for Dyskinesia - Drug Profile 114

Small Molecules to Target Ion Channels for CNS Disorders - Drug Profile 115

SOM-3355 - Drug Profile 116

TC-8831 - Drug Profile 117

tetrabenazine - Drug Profile 118

valbenazine tosylate - Drug Profile 119

Dyskinesia - Dormant Projects 127

Dyskinesia - Discontinued Products 129

Dyskinesia - Product Development Milestones 130

Featured News & Press Releases 130

Appendix 143

Methodology 143

Coverage 143

Secondary Research 143

Primary Research 143

Expert Panel Validation 143

Contact Us 143

Disclaimer 144

List of Tables

List of Tables

Number of Products under Development for Dyskinesia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Dyskinesia – Pipeline by Adamas Pharmaceuticals Inc, H2 2017

Dyskinesia – Pipeline by Addex Therapeutics Ltd, H2 2017

Dyskinesia – Pipeline by Advicenne SA, H2 2017

Dyskinesia – Pipeline by Avanir Pharmaceuticals Inc, H2 2017

Dyskinesia – Pipeline by Bionomics Ltd, H2 2017

Dyskinesia – Pipeline by Catalyst Biosciences Inc, H2 2017

Dyskinesia – Pipeline by Cavion LLC, H2 2017

Dyskinesia – Pipeline by Clevexel Pharma SAS, H2 2017

Dyskinesia – Pipeline by EpiVax Inc, H2 2017

Dyskinesia – Pipeline by Heptares Therapeutics Ltd, H2 2017

Dyskinesia – Pipeline by Ipsen SA, H2 2017

Dyskinesia – Pipeline by Merz Pharma GmbH & Co KgaA, H2 2017

Dyskinesia – Pipeline by Neurim Pharmaceuticals Ltd, H2 2017

Dyskinesia – Pipeline by Neurocrine Biosciences Inc, H2 2017

Dyskinesia – Pipeline by Neurolixis Inc, H2 2017

Dyskinesia – Pipeline by Osmotica Pharmaceutical Corp, H2 2017

Dyskinesia – Pipeline by Phenomenome Discoveries Inc, H2 2017

Dyskinesia – Pipeline by Sage Therapeutics Inc, H2 2017

Dyskinesia – Pipeline by SciFluor Life Sciences LLC, H2 2017

Dyskinesia – Pipeline by SOM Biotech SL, H2 2017

Dyskinesia – Pipeline by Synchroneuron Inc, H2 2017

Dyskinesia – Dormant Projects, H2 2017

Dyskinesia – Dormant Projects, H2 2017 (Contd..1), H2 2017

Dyskinesia – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Dyskinesia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports